Triple-targeted therapy (dabrafenib, trametinib plus 3rdEGFR TKIs) could be considered the preferential treatment options for acquired BRAF/EGFR co-mutated and primary BRAF/EGFR non-19del co-mutated NSCLC patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.